Synaptogenix (NASDAQ:TAOX – Get Free Report) released its earnings results on Monday. The company reported $0.38 EPS for the quarter, Zacks reports. Synaptogenix had a negative net margin of 2,153.97% and a negative return on equity of 128.51%.
Synaptogenix Stock Performance
TAOX traded down $0.24 during trading on Monday, reaching $1.86. The company had a trading volume of 88,871 shares, compared to its average volume of 155,319. The firm’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $4.16. The company has a market cap of $14.96 million, a price-to-earnings ratio of -0.48 and a beta of 1.81. Synaptogenix has a 12-month low of $1.70 and a 12-month high of $7.85.
Analyst Ratings Changes
TAOX has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, October 15th. Wall Street Zen downgraded Synaptogenix from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has an average rating of “Sell”.
Check Out Our Latest Research Report on TAOX
Synaptogenix Company Profile
Synaptogenix was a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and disorders involving impaired cognitive function. The company’s research centered on therapies intended to support synaptic function. Its lead investigational drug candidate was bryostatin-1, which it studied as a potential treatment for Alzheimer’s disease. The company also explored its approach in other conditions associated with cognitive impairment. Bryostatin-1 was investigational, not an approved medicine.
Read More
- Five stocks we like better than Synaptogenix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
